* U.S. FDA advisory panel votes to reject Depomed's Sefelsa
* Panel also rejects Noven Pharmaceuticals menopause drug
* Advisors say neither drug confers enough benefit
* Depomed shares fall 9.8 percent
WASHINGTON, March 4 (Reuters) - Advisers to the U.S. Food and Drug Administration on Monday voted against approval of two drugs designed to reduce the frequency and severity of hot flashes associated with menopause, concluding that neither conferred enough benefit to offset their risk.
The panel voted 12-2 against a drug made by Depomed Inc, sending the company's shares down 9.8 percent to $5.89 on the Nasdaq. Depomed's shares fell as low as $5.12 immediately after they resumed trading following a halt pending the results of the panel's meeting.
The panel also voted 10-4 against approving a drug for hot flashes made by Hisamitsu Pharmaceutical Co Inc's subsidiary Noven Pharmaceuticals Inc.
The drugs would have been the first non-hormonal therapies for hot flashes to have been approved by the FDA. The use of hormone therapy has dropped significantly since 2002, when findings from a large clinical trial showed the therapies could increase the risk of heart attack and stroke.
Hot flashes affect some 75 percent of the estimated 32 million women in the United States experiencing menopause each year, Depomed said. Hot flashes, characterized by warmth, flushing and sweating, can be disruptive, and can last anywhere from a few years to more than a decade.
CONCERNS ABOUT SUICIDE RISK
Depomed's drug, Sefelsa, is a long-acting version of the epilepsy drug gabapentin. A short-acting version of gabapentin, made by Pfizer Inc and marketed as Neurontin, was approved in 1993.
Clinical trials of Sefelsa showed it only partially reduced the frequency and severity of hot flashes, while side effects included dizziness, sleepiness, headache and nausea. Gabapentin has also been shown to increase the risk of suicide.
Similarly, Noven's drug did not meet all the goals it was supposed to meet in a clinical trial and panel members felt it was difficult to assess how beneficial the treatment was since many patients taking the placebo also improved.
The FDA does not have to follow the recommendations of its advisory panels, but it generally does.
Depomed said it would cease spending on Sefelsa.
"We recognize and appreciate the concerns that were raised by the members of the Advisory Committee," Jim Schoeneck, Depomed's chief executive officer, said in a statement. "Based on today's meeting, we believe the hurdles for approval of a non-hormonal treatment for hot flashes remain high."
Extended-release gabapentin was approved in the United States in 2011 to treat shingles-related pain. It is marketed by Depomed under the brand Gralise.
Noven's drug comprises a low dose of the antidepressant paroxetine mesylate. The company sells a higher-dose version of the drug under the brand Pexeva for, among other things, depression, obsessive-compulsive disorder and generalized anxiety. A similar drug, Paxil, is made by GlaxoSmithKline Plc.
"The FDA's advisors did a great job today of carefully considering the scientific evidence," said Diana Zuckerman, president of the National Research Center for Women & Families, a nonprofit organization that promotes health and safety of children and adults.
"We strongly urge the FDA to listen to these advisors and reject the applications of both companies."
Risks associated with paroxetine include an increase in suicidal thinking.
"While we are disappointed in today's outcome, we appreciate the discussion and will work closely with the FDA as it completes its ongoing evaluation," said Dr. Joel Lippman, Noven's chief medical officer.
He reiterated the company's belief that the trial data support the use of the drug as safe and effective.
(Reporting by Toni Clarke; Editing by Gerald E. McCormick, Sofina Mirza-Reid, Dale Hudson and Jan Paschal)
Copyright 2013 Thomson Reuters. Click for Restrictions.
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.